Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Invest in Cases Systematically - Every stock is handpicked
Start Buying Now
Start Buying Now
Cipla is currently trading at Rs. 570.70, up by 4.70 points or 0.83% from its previous closing of Rs. 566.00 on the BSE.
The scrip opened at Rs. 566.00 and has touched a high and low of Rs. 573.05 and Rs. 561.75 respectively. So far 44,225 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 660.00 on 29-Dec-2015 and a 52 week low of Rs. 458.25 on 25-May-2016.
Last one week high and low of the scrip stood at Rs. 581.05 and Rs. 560.00 respectively. The current market cap of the company is Rs. 45,899.52 crore.
The promoters holding in the company stood at 36.74%, while Institutions and Non-Institutions held 35.31% and 26.64% respectively.
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Fenofibrate Tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA). Fenofibrate Tablets, USP 48mg and 145mg, are AB-rated generic equivalents of AbbVie’s Tricor Tablets and are indicated as adjunctive therapy to diet to reduce elevated low-density lipoproteincholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Tricor Tablets and generic equivalents had US sales of approximately $307M for the 12 month period ending October 2016. Cipla’s Fenofibrate Tablets will be available for commercial shipment in the US in the coming weeks.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
